DiaSorin: Anticipate A Double-Digit EBITDA Growth Rate

2025-05-02 10:30:00 ET

Summary

• DiaSorin's 2024 revenue grew by 3%, with an underlying increase of 7%, and net profit rose to 188.1M EUR, reflecting a 17% EPS increase.
• The company generated strong free cash flow of 191M EUR, enabling potential M&A activities to support future growth.
• DiaSorin's 2025 guidance targets a 7% revenue increase and a 34% adjusted EBITDA margin, with plans to reach a 36-37% margin by 2027.
• I believe DiaSorin's robust business model and strategic M&A could achieve high single-digit revenue growth, making it a quality investment opportunity.

Introduction

DiaSorin ( OTCPK:DSRLF ) is one of the world’s largest diagnostics companies (including immunodiagnostics and molecular diagnostics) with revenues generated from sales to hospitals and universities. Meanwhile, its licensed technologies division offers third parties access to its proprietary technology. As a diagnostics company, DiaSorin definitely benefited from the COVID pandemic, and until this day still generates some revenue from COVID-related testing. ...

Read the full article on Seeking Alpha

For further details see: